On March 10 the FDA approved Trofinetide, a drug based on the protein IGF-1. The MIT professor's original research showing that IGF-1 could treat Rett was published in 2009.
With 75 years of aviation industry-focused research and education under its belt, the lab continues to develop propulsion systems for next-generation aircraft.